Arjuna Natural Ltd. has been granted a new patent in Europe for its applied technology improving the bioavailability of curcumin in its BCM-95 (Curcugreen) formulation.
 
The new patent enables Arjuna to further expand its stronghold in 20 additional countries across Western and Eastern Europe. It is already protected 14 patents in the U.S., two in Japan, and 33 in European Countries for composition and manufacturing processes of curcumin extract. The patented formulation provides biologically active curcumin with the essential oil of turmeric.  The 100% natural formulation is backed by over 55 published studies and several on-going studies for its therapeutic activity in multiple health indications.   
  
“The composition of BCM-95 (Curcugreen) contains only turmeric based components and no synthetic or non-turmeric ingredients,” said Benny Antony, PhD, joint managing director for Arjuna. “This composition of turmeric delivers free curcumin into the blood and is retained in the body for a longer duration.”
 
This patent in effect helps to address much confusion in the market regarding curcumin absorption and oral bioavailability. The main problem of curcumin is that it is not absorbed nor retained well in the bloodstream.  Yet, the market has subsequently been flooded with curcumin products laden with synthetic additives in attempts to overcome the issue of bioavailability. 
 
“Any supplement you put into your body should be both safe and effective,” insisted Antony. “Arjuna’s BCM-95 (Curcugreen) is wholly manufactured in its own facility under a fully automated cGMP complied continuous extraction plant—using only solar power. This has enabled Arjuna to triple its manufacturing capacity in Coimbatore, India to meet the growing demand for their brand of curcumin in the coming years.